Donor pretreatment with anti-T-cell receptor monoclonal antibodies prevents graft-vs-host disease in brequinar-treated small bowel allograft recipients.
Wang
M
M
Department of Surgery, University of Texas Medical School at Houston 77030.
Stepkowski
S M
SM
Kahan
B D
BD
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000494:pharmacology*; D001713:Biphenyl Compounds / Q000627:therapeutic use*; D006085:Graft Survival / Q000276:immunology; D006086:Graft vs Host Disease / Q000517:prevention & control*; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D007421:Intestine, Small / Q000637:transplantation*; D051381:Rats; D011914:Rats, Inbred BN; D011917:Rats, Inbred Lew; D016693:Receptors, Antigen, T-Cell, alpha-beta / Q000276:immunology*; D014184:Transplantation, Homologous / Q000276:immunology*; D011798:Quinaldines
D000911:Antibodies, Monoclonal; D001713:Biphenyl Compounds; D007166:Immunosuppressive Agents; D016693:Receptors, Antigen, T-Cell, alpha-beta; C046943:brequinar; D011798:Quinaldines